Wow, what a very interesting experience at the All-Virtual 62nd ASH Annual Meeting and Exposition (ASH). The total number of ASH abstracts for 2020 was 4800, down from last year’s 6000. There were 688 Myeloma Abstracts. 179 of them were oral abstracts, which are presented in 15-minute time slots. There were 500 poster abstracts, which […]
“We weren’t sure what this coronavirus would do because we’ve never witnessed a pandemic of a coronavirus before. Now we know it’s kind of a super forest fire. It just keeps burning and burning and burning wherever there is human wood.” — Michael T. Osterholm, Phd, MPH Due to the ongoing COVID-19 pandemic, ASH 2020 […]
This year’s ASH, as we all know, has been very different, thanks to Covid-19. We’ve missed lots of things by not being physically together; however, there are always silver linings! I’m mostly grateful to the resilient researchers, hematologists/oncologists, nurses, and pharmaceutical companies that have keep research going through this pandemic. While there were fewer abstracts at ASH this […]
Attending the ASH IMF Satellite Symposium, “Accelerating Toward Curing Myeloma: New Data, New Agents, and Evolving Treatment Paradigm,” on Friday afternoon reminded me once again why I enjoy attending ASH. Primarily because it gives me hope: Hope in knowing that the experts are working so hard to find the best treatment, hope in seeing the […]
